

IVD



## FluoroType<sup>®</sup> MTBDR VER 2.0

- Powered by **LiquidArray<sup>®</sup>**

Single-tube high-multiplex PCR and subsequent fluorescence-based detection of *M. tuberculosis* complex and its resistance against rifampicin and isoniazid from sputum specimens or cultivated samples.

### Your benefits of using FluoroType<sup>®</sup> MTBDR

- **Novel technology:** The test system is based on the innovative LiquidArray<sup>®</sup> technology. It thus enables reliable MDR-TB diagnostics within 2.5 hours only.
- **True MDR-TB testing:** Resistances to both first-line drugs, rifampicin and isoniazid, are reliably identified, as well as mono-resistances.
- **Reliable results:** The assays can detect silent mutations within the *rpoB* gene and therefore allows confidence when testing for resistance.
- **Flexible and intelligent software:** The user-friendly and machine learning, specific FluoroSoftware<sup>®</sup> XT-IVD does the evaluation and interpretation. A high number of resistance-mediating mutations is specified within the result report. In addition, rare or so far unknown mutations in the target genes are also shown.
- **Automated workflow solution:** Bruker's FluoroCycler<sup>®</sup> XT in combination with GenoXtract<sup>®</sup> fleXT\* enables high throughput automated workflow from extraction to detection.

## Facts

Multidrug-resistant tuberculosis (MDR-TB) is an alarming and ongoing global issue which requires fast intervention in order to prevent further spread of the disease. More and more frequently, mono-resistant strains are found. Thus, utilising a test system that provides rapid and reliable results for the two most important first-line drugs, rifampicin and isoniazid, allows clinicians to make an informed decision on how to treat their patients with the most appropriate therapy.

### Test principle of FluoroType® MTBDR




FluoroType® MTBDR is the first assay based on the unique LiquidArray® technology.

Within one reaction the test allows for the detection of *M. tuberculosis* complex and identification of mutations within the *rpoB*, *inhA* and *katG* genes. By using the LiquidArray® technology, also rare or so far unknown mutations in the target genes can be reliably detected. Additionally, it is possible to enter information on novel mutations into the machine learning software in order to ensure their specification in the future.

DNA extraction can be performed manually using FluoroLyse or fully automated with the GenoXtract®. A fully automated DNA extraction together with PCR set-up is possible with the GenoXtract® fleXT\*. The plate is placed directly into the FluoroCycler® XT for amplification and detection. An Internal

Control documents the correct test procedure and valid results.

The results are evaluated and displayed in the FluoroCycler® XT Report. Fully automated, fast and reliable results at one glance are therefore guaranteed.



*\*Coming soon. This product may have become available in the meantime. Please contact us for further information. The information in this flyer is correct as of June 2022.*

Please contact your local representative for availability in your country. Not for sale in the USA.  
FluoroType®, FluoroCycler® and GenoXtract® are registered trademarks of Bruker corporate group  
GenoXtract® fleXT Hamilton Bonaduz AG, Via Crusch 8, CH-7402 Bonaduz, Switzerland  
FluoroCycler® XT Hain Lifescience, Hardwiesenstrasse 1, 72147 Nehren, Germany

### Hain Lifescience GmbH

Hardwiesenstrasse 1  
72147 Nehren - Germany  
Phone +49 (0) 7473-9451-0

[info.mdx.de@bruker.com](mailto:info.mdx.de@bruker.com) - [www.hain-lifescience.de](http://www.hain-lifescience.de)